RUNX1–ETO Upregulates CCND2 to Drive Leukemogenesis

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-180
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Targeting the Oligomerization Domain of ETO Interferes With RUNX1/ETO Oncogenic Activity in T(8;21)-Positive Leukemic Cells

Cancer Research
Cancer ResearchOncology
2007English

Paradoxical Enhancement of Leukemogenesis in Acute Myeloid Leukemia With Moderately Attenuated RUNX1 Expressions

Blood advances
Hematology
2017English

A Minicircuitry of microRNA-9-1 and RUNX1-RUNX1T1 Contributes to Leukemogenesis in T(8;21) Acute Myeloid Leukemia

International Journal of Cancer
Cancer ResearchOncology
2016English

Dnmt3a Deletion Cooperates With the Flt3/Itd Mutation to Drive Leukemogenesis in a Murine Model

Oncotarget
Oncology
2016English

Increased Dosage of Runx1/Aml1 Acts as a Positive Modulator of Myeloid Leukemogenesis in BXH2 Mice

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

CHAF1B Suppresses Myeloid Differentiation to Promote Leukemogenesis

Cancer Discovery
Oncology
2018English

Discovering Early Molecular Determinants of Leukemogenesis

Journal of Clinical Investigation
Medicine
2008English

Leukemogenesis by Ionizing Irradiation

Acta Radiologica
1954English

NHR4 Domain Mutations of ETO Are Probably Very Infrequent in AML1–ETO Positive Myeloid Leukemia Cells

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy